Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases

The transfusion of neutrophils, or granulocyte transfusion therapy, has lon g been considered as a logical approach to the treatment of severe bacteria l and fungal infections in patients with prolonged neutropenia or intrinsic defects in neutrophil function. However, despite numerous clinical trials, the efficacy and safety of granulocyte transfusion therapy remain controve rsial. Efficacy has been compromised largely by the inability to transfuse sufficient quantities of functionally active neutrophils to patients. The r ecent use of recombinant granulocyte colony- stimulating factor (G- CSF) to mobilize neutrophils in donors before centrifugation leukapheresis has rek indled interest in the potential clinical applications of granulocyte trans fusion therapy. This review focuses on the use of G- CSF for donor stimulat ion and summarizes the current status of granulocyte transfusion therapy fo r treatment of infectious diseases.